Member Info for NFTs

Too many looking at the SP on the AIM soup and think that relates to the businesses progress and value.

This is just TA wobble and watch this move as we progress towards the 22nd

Anyone wants to think that Richard Hughes has taken the Chairman’s role here to watch a flop is either stupid or intentionally ignorant to what is coming.

AVACTA is a beast and it’s really it long now till we see a gem of the AIM produce history here.

Ignore the sockpuppets like wyndrum as they are only intentionally trying to cause doubt to aid their trading

The Guardian headline is a classic example of mainstream science journalism: it takes a genuinely fantastic result for a very specific subset of patients and writes a headline that makes it sound like a universal cure.

The "jab" the article refers to is a drug called amivantamab (developed by Johnson & Johnson). It is a highly effective treatment, but it addresses a completely different biological mechanism than Avacta’s pre|CISION platform. 

Here is why Avacta's position in the oncology market remains entirely intact.

The "Jab" (Amivantamab) Targets Specific Mutations

Amivantamab is a bispecific antibody—a type of targeted immunotherapy. It is designed to hunt down cancer cells that express two very specific proteins on their surface: EGFR and MET. 

When a patient has a tumor heavily driven by these specific receptors (which is common in certain head and neck, and non-small cell lung cancers), amivantamab is incredibly effective at shrinking or eradicating the tumor. However, if a patient’s tumor does not express EGFR or MET, this jab is virtually useless to them. It is a highly specialized key for a very specific lock.

Avacta’s pre|CISION is a Universal Delivery Mechanism

As you noted, Avacta’s pre|CISION platform has a vastly different and broader application.

Instead of looking for rare genetic mutations on the cancer cells themselves, Avacta targets Fibroblast Activation Protein (FAP). FAP is an enzyme present in the "tumor microenvironment"—the connective tissue that surrounds and supports almost all solid tumors, regardless of the cancer's specific genetic mutations.

Avacta isn't just making one drug; they are making a delivery system. They take highly toxic chemotherapies (like doxorubicin in AVA6000, or exatecan in AVA6103), attach them to a chemical padlock, and make them completely harmless while circulating in the bloodstream. The chemotherapy is only released when it hits the FAP in the tumor microenvironment.

Head-to-Head Comparison

| Feature | Amivantamab (The Guardian's "Jab") | Avacta pre|CISION (e.g., AVA6000, AVA6103) |

| :--- | :--- | :--- |

| Treatment Type | Bispecific Antibody (Immunotherapy) | Peptide Drug Conjugate (Targeted Chemo Delivery) |

| What it Targets | EGFR and MET proteins on the cancer cell | FAP enzyme in the surrounding tumor tissue |

| Applicability | Narrow: Only works on cancers expressing those specific receptors | Broad: FAP is upregulated in the vast majority of solid tumors |

| Mechanism | Blocks growth signals and triggers the immune system | Cleaves a chemical bond to release toxic chemotherapy directly into the tumor |

The Reality of the Oncology Market

Cancer is not a single disease, which means there is no "winner takes all" drug. A breakthrough in an EGFR-targeted therapy does not cannibalize the market for a FAP-targeted chemotherapy delivery platform.

If anything, Avacta’s fundamental value proposition has only strengthened recently. At the American Association for Cancer

That’s the snake, no good trying multiple accounts to dilute. Sssssssssss

Oh I see the resident two headed snake is trying to continue to pretend it’s not him. We know who you are now so best stop digging that hole any bigger.

Oh, I see the snake is back. Sssssssssssss two face rat

On the morning of the abstract the company will RNS the new data.

The abstract currently being seen now not the new data obviously.

People just have to wait!!!

Again, they just cannot adjust analysis for proven drugs. It’s crazy basics. Yet every kid in the city reads from the same playbook.

Trinity Delta’s Latest Valuation for Avacta (AVCT)

Trinity Delta’s latest updated valuation for Avacta stands at £471 million ($603 million), which equates to 103p per share (or 90p per share on a fully diluted basis). This updated model reflects the cash received and increased share count following the company's recent oversubscribed £10m equity raise. 

The Best Brief Bits from the Latest Report (May 19, 2026)

Avacta released its preliminary FY25 results yesterday, and Trinity Delta subsequently updated their research note. Here are the absolute most important takeaways for investors: 

Cash Runway is Secured: Avacta had £16.4m in cash at the end of April 2026. Boosted by £32.5m in equity raised over the last 18 months, their funding runway now extends into early Q1 2027. This is critical because it carries them past several major pipeline catalysts without immediate dilution fears. 

Imminent AVA6000 (Gen One) Catalysts: Expect major data drops in H1 2026. This will include updated Phase 1a and 1b efficacy data in expansion cohorts (primarily for salivary gland cancer). Crucially, the highly favorable cardiac safety data has already resulted in health authorities removing the lifetime maximum dose limit for this drug. 

**AVA6103 (Gen Two) is in the Clinic: The first patient was successfully treated in the FOCUS-01 Phase 1 clinical trial in March 2026. Preclinical data has been highly favorable, even when stacked against successful approved antibody-drug conjugates (ADCs) like Enhertu. 

Active Partnering Discussions: The company confirmed they are in ongoing discussions with multiple parties regarding potential commercial partnering for their first, second, and third-generation (dual payload) pre|CISION assets. 

In short: The funding overhang has been cleared, they retain 100% ownership of their pipeline, and the next 6–12 months are packed with critical clinical data readouts that will heavily dictate the stock's momentum.

Nearly every single analyst report and valuation etc they all make one very basic fundamental mistake.

They have one model they use and thats basing the data and trials as if they are new drugs.

This is outright wrong analysis and it’s so important.

You cannot base AVACTA trials as if they are on the same risk basis.

Every single one use the COS as if its new drugs.

It’s about time the pharmaceutical analysis world when trying to base risk on companies like this update their views.

You pass phase one safety data with precision using known drugs then the rest becomes inevitable as the drug data in the body has already been done by pharmaceutical years earlier.

Precision is now 100% proven. Once you then trial phase 1 with each molecule, as long as it delivers to target then we know the rest.

The fact we are already this far on AVA6103 the value inflection point is already here.

Touk having multiple ID’s is against LSE rules. Since Ophid 🐍 account is joint account you should be banned from posting. But I suspect you use multiple devices under VPN’s

This doesn’t negate how script shows who you are and timing of how it started aligns.

Remember you have no idea on the science do you now!!!

"• AVA6000 clinical data from the Phase 1a and 1b cohorts are expected in H1 2026 - including updated efficacy data in expansion cohorts, the lead indication of salivary gland cancer, and cardiac safety data which resulted in removal of lifetime maximum dose limit."

"Further data will be presented by the end of the 1H 2026, in particular an update on the Phase 1b cohorts, including the lead indication, salivary gland cancer. In addition, we will present the full cardiac safety data and clinical pharmacology data that led to the lifting of the cardiac dosing limitation."

"We expect multiple data updates in the AVA6000 program in all groups from the Phase 1b expansion cohorts, in H1 2026."

The last part tells you all you need.

They are within next 5 weeks.

People have already replied.

It’s past not fwd year. It states readouts this H1 in two stages

it is completely normal to notice an omission like that, but you should not necessarily read it as a failure or a red flag for triple-negative breast cancer (tnbc).

here is why salivary gland cancer (sgc) is completely dominating the narrative in this specific report, and what is actually happening with tnbc:

1. sgc is the "path of least resistance" to approval

during the earlier phase 1a trials, the data for sgc was so overwhelmingly positive (a 90% disease control rate) that avacta immediately elevated it to their lead indication. sgc is an orphan disease with virtually no established standard of care for metastatic patients. by focusing heavily on sgc, avacta can pursue an accelerated regulatory pathway (potentially moving straight to a registrational trial) much faster than they could in a highly competitive, crowded space like breast cancer. 

2. the tnbc data is still maturing

avacta's phase 1b expansion cohort specifically targets three cancer types: sgc, soft tissue sarcoma, and tnbc. prior company guidance from mid-2025 stated that the initial phase 1b data for tnbc was expected in h1 2026. because this report is a high-level summary looking backward at the fy25 timeline, they are highlighting the sgc data that was officially published and finalized in december 2025. 

3. saving ammo for medical conferences

biotech companies rarely drop brand-new, highly anticipated efficacy data in a routine end-of-year financial preliminary report. if they have tnbc data coming in h1 2026 (which we are currently in), they are likely holding it for a dedicated press release or a major medical conference (like asco in june) to maximize its impact.

the bottom line:

they mention they are continuing to enroll the phase 1b expansion cohorts in "more ****genous, defined patient populations" (which includes tnbc). sgc is taking the spotlight simply because it is the strongest, most mature data they have to prove the platform works, and it offers the quickest route to commercialization.

Major Clinical Breakthroughs

• Safety Restriction Lifted (AVA6000): Health authorities officially removed the lifetime maximum dose limit for their lead doxorubicin drug due to "highly favorable cardiac safety" results. They also reported a 90% disease control rate in salivary gland cancer patients.

• Next-Gen Trial Begins (AVA6103): As of March 2026, the first patient was treated with their Gen Two drug. This features a brand-new sustained release mechanism designed to prolong the drug's release directly inside the tumor while minimizing toxic exposure to the rest of the body.

• "Dual-Payload" Innovation (Gen Three): Avacta has successfully advanced its pre|CISION platform to deliver two different cancer-fighting payloads simultaneously from a single delivery mechanism.

💼 Strategic & Financial Shifts

• Now a "Pure-Play" Oncology Company: Avacta finalized the sale of its non-core diagnostics businesses (Launch Diagnostics and Coris BioConcept) for a combined £15.1 million to focus 100% on cancer therapeutics.

• Secured Cash Runway: The company raised £22.5 million in 2025 and completed an oversubscribed £10 million raise in March 2026. This £32.5 million total cash injection extends their operational runway into Q1 2027.

• AI Integration: Avacta is leveraging a strategic collaboration with Tempus AI to select trial patients and build "synthetic comparator arms"—allowing them to compare their drugs against blockbuster competitors like Enhertu® and Datroway® without running redundant experiments.

• C-Suite Overhaul: The company significantly strengthened its leadership, appointing a new Chief Financial Officer (Jan 2025), Chief Medical Officer (July 2025), and Chief Scientific Officer (Feb 2026).

The upcoming 9–12 months are described as a "crucial and transformative" period for the company. Here is the exact timeline of what they are projecting next:

📅 H1 2026 (Imminent)

• AVA6000 Data Drop: Expecting clinical data updates from the Phase 1a and 1b cohorts. This will include the full cardiac safety data (explaining why regulators lifted the dose limit) and updated efficacy data for the lead salivary gland cancer indication.

📅 H2 2026

• Gen Three Selection: Payload and clinical candidate selection for the newly developed Gen Three Dual Payload program (AVA6207).

• Late H2 2026: First-ever initial clinical data from the newly started AVA6103 (Gen Two sustained-release) program.

🤝 Ongoing Commercial Focus

• Strategic Partnerships: The company explicitly notes they are in active, ongoing discussions with multiple pharmaceutical parties to partner or out-license their first, second, and third-generation drug assets to generate near-term revenue.

Absolutely. I could do a piece on that alone.

Purely and simply due to the fact AVACTA are repurposing existing known drugs the value and threat factor is also multiples higher.

Even now AVACTA is a strategic threat to all ADC market that address the 90% of solid tumours.

So they are all threatened right now.

AZ either buy and protect or another buys and destroys huge revenue to AZ.

Even now AVACTA strategically is worth an offer between 5 and 10 billion.

When the very first data arrives on AVA6103 that changes instantly to being a direct competitor to taking the market.

Why, because these drugs will behave like already known so by reducing the exposure and proving the model as to AVA6000 the majors will already know enough.

At that point AVACTA immediately drops to Seagen level of acquisition. Above that it becomes very hard for majors to rustle up more than 45 billion.

But this is exactly where this platform will be upon replication of the data end of this year.

• Superior Tumor Penetration: Because PDCs are a fraction of the size of ADCs, they penetrate dense solid tumors much more effectively. Early data suggests AVA6103 achieves maximum tumor drug concentrations (C_{max}) significantly higher than Enhertu.

• Agnostic Targeting: AVA6103 targets the FAP-rich tumor stroma, present in up to 90% of epithelial tumors. It is not bottlenecked by the need for specific biomarkers like HER2, HER2-low, or TROP2, potentially giving it a vastly wider addressable market.

The Strategic Verdict: Threat or Target?

Avacta is not going to erode AstraZeneca’s revenue in 2026 or 2027. Enhertu’s position in early-stage breast cancer is locked in for the near future.

However, Avacta is an existential threat to the next generation of AstraZeneca’s pipeline. If AVA6103 replicates its preclinical superiority and the safety profile of AVA6000 in human trials, the pharmaceutical industry will realize that PDCs represent an evolution over ADCs.

Therefore, Avacta's ultimate role is likely not as a standalone competitor, but as a premium M&A target. AstraZeneca (or competitors like Merck, Pfizer, or Novartis who missed the first ADC wave) will view Avacta's platform as a necessary acquisition to secure the next decade of oncology dominance. The 4.5 years of precision data and the FDA's regulatory nod have de-risked the platform entirely.

AstraZeneca’s Enhertu is currently an undisputed juggernaut in the Antibody-Drug Conjugate (ADC) space, further entrenched by the FDA's recent 2026 approvals moving it into the early, curative-intent breast cancer setting.

However, Avacta represents a profound, medium-to-long-term structural threat to the entire ADC class—and by extension, AZ’s future oncology pipeline. With the FDA’s historic lifting of the lifetime cumulative dosing limit on AVA6000 (doxorubicin) validating the cardiac safety of the pre|CISION® platform, and AVA6103 entering the clinic, Avacta has proven that Peptide-Drug Conjugates (PDCs) can solve the exact toxicity and delivery bottlenecks that currently plague ADCs like Enhertu.

AstraZeneca’s Commercial Moat: The Enhertu Juggernaut

To understand the threat level, we must first quantify AstraZeneca’s current market insulation. The May 2026 RNS highlights a formidable clinical and commercial fortress:

• Standard of Care Entrenchment: Enhertu has secured approvals across six breast cancer indications in seven years, moving from late-stage salvage therapy to early-stage curative intent (DESTINY-Breast11 and DESTINY-Breast05).

• Scale and Infrastructure: Approved in over 95 countries, AZ and Daiichi Sankyo possess unmatched global manufacturing, distribution, and commercialization infrastructure.

• Clinical Momentum: The sheer volume of data AZ has generated makes Enhertu the default Category 1 recommendation in NCCN guidelines. Dislodging a Category 1 standard of care requires years of Phase III head-to-head superiority data.

The Vulnerability: Enhertu’s Achilles' heel remains its toxicity profile. In the DESTINY-Breast05 trial, adjudicated drug-related interstitial lung disease (ILD)/pneumonitis occurred in 9.6% of patients, resulting in two fatalities. Furthermore, Enhertu relies on the presence of the HER2 antigen, limiting its total addressable market to specific patient subgroups.

Avacta’s Disruptive Edge: The PDC Paradigm

Avacta’s pre|CISION® technology fundamentally alters how toxic payloads are delivered to the tumor microenvironment (TME). Instead of relying on a bulky antibody targeting a specific cell-surface antigen (like HER2), AVA6103 uses a peptide cleaved exclusively by Fibroblast Activation Protein (FAP), which is highly concentrated in the stroma of most solid tumors.

This creates three critical advantages over current ADCs:

• Unprecedented Safety (The AVA6000 Precedent): The FDA’s decision to lift the lifetime dosing cap on AVA6000 is a watershed moment for oncology. Doxorubicin is notoriously cardiotoxic. By proving they can dose it heavily without cardiac damage, Avacta has clinically validated that the pre|CISION® platform shields healthy tissue from highly toxic payloads.

P2/2

Hey Touk you would know though wouldn’t as you know all about the science. You little ruse of a snake 🐍 hiding, pretending you’re not Oph!!!!

And here you are in plain sight. What a horrid individual you truly are. Hope all that associate with you now realise what you have been playing here.

What a pathetic old man you are.

Absolutely snake slithering around lying. The worst kind. You have such a sly hissy jealous side.

Oh you know nothing about the science hey!!! What a crook. I hope all who connect understand the implications of who this individual really is. Quietly attacking those behind their backs while smiling with the forked tongue of poison.

Ignore all these double tongued players like the main snake himself who has now been exposed.

The company is walking a mighty fine path. Guided by a particular credible city player Richard Hughes.

They are delivering now in so many ways. How they build the MCAP will be mapped out. We know they need a deal on AVA6000, either just STS or all indications.

They have options. These next weeks will be significant period in helping achieve a more substantial MCAP towards the big one, AVA6103.

The curveball being that majors like AZ understand completely what is going on here and will imo deciding how to approach. Company will not sell until that data is produced. Rightly so, as that’s worth multiples if we get what we believe.

HCI are completely in their rights to convert, they will do this as and when they see opportunity. Each time carefully done so it doesn’t pull the SP down too hard, but each time it reduces debt and becomes completely irrelevant. So it’s a win. If your mortgage was 4% of your house price, would you worry?

Not off my trolly Touk

You are a snake in name and it’s clear in the analysis of you writing style.

What a snake. 🐍